BioVerse 19：专家共话肥胖药物研发趋势

E药经理人 · 公众号 · 医学 · 2025-03-10 19:50

正文

Why should you attend?

· Over 1 billion people would be obese by 2030, making obesity a ~ $150 billion market opportunity.

· Gain exclusive perspectives from from no.1 wall-street analyst, a veteran obesity biotech founder, and an obesity intelligence expert.

· Hear the insights into the key catalysts and debates about the key trends in this space, ranging from marketed products to emerging targets.

· Learn about the hot topics tailored for professionals in the pharmaceutical, investment, consulting, and research industries.

Who should attend?

· Professionals in pharma and biotech, including business development executives, licensing managers, R&D leaders, and corporate strategists.

· Investors, venture capitalists, M&A analysts, and deal advisors.

· Academic researchers involved in cross-border biotech collaborations.

· Industry professionals interested in leverage Asian biotech innovations.

Event details

主题： BioVerse Episode 19 - The Current Trends in Obesity Drug Development

时间: Mar 13 ^th , 2025, 12-1 PM ET (Live ) / Mar 14 ^th , 2025, 8-9 PM BJT (Replay)

Networking with speakers/attendees on LinkedIn:

https://www.linkedin.com/events/bioverseepisode19-thecurrenttre7301558358761750528/attendees/

地点: 微解药APP（扫描二维码或点击文末“阅读原文”观看）

Speakers intro

Umer Raffat, MS

Senior Managing Director

Umer Raffat is a senior managing director at Evercore ISI and heads the large-cap therapeutics effort spanning biotech companies as well as major pharmaceuticals and specialty pharmaceuticals.

As of 2024, Mr. Raffat has been ranked No. 1 on 22 separate occasions by Institutional Investor (now Extel), starting from his first year covering the sector. He is top ranked across all categories he covers: large-cap biotech, major pharmaceuticals and specialty pharma.

He started his equity research career under Dr. Mark Schoenebaum at Deutsche Bank in 2010, and they moved together to Evercore ISI.

In 2020, Mr. Raffat was inducted into Institutional Investor’s All-America Research Team Hall of Fame, a designation for analysts who have earned a No. 1 ranking on at least 10 occasions.

Mr. Raffat has an undergraduate degree in biology from University of Texas at Arlington and a master’s from Harvard School of Public Health.

Xiayang Qiu, PhD

CEO & Founder

Dr. Xiayang Qiu, founder and CEO of Regor Therapeutics Group, has a remarkable track record in structure-based drug design across therapeutic areas and modalities. The Regor Computer Accelerated Rational Discovery – rCARD – technology platform he established with his cofounders has already delivered the unique CDK4+ inhibitor RGT-419B, recently in-licensed by Roche for $850M up-front + milestones, and the leading oral small molecule GLP-1R full agonist RGT-075 for obesity and other metabolic diseases. Regor also has pipeline candidates focused on other prominent targets and particular unmet needs (STING, HPK and others).